A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Inclusion Criteria
Exclusion Criteria
Ciudad de Buenos Aires, Buenos Aires 1180, Argentina
Quilmes, Buenos Aires F.D. 1879, Argentina
SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
Secundarabad, Telangana 500003, India
Eiheiji-cho,Yoshida-gun, Fukui 910-1193, Japan
Kita, Kagawa-ken 761-0701, Japan
Shimotsuga, Tochigi 321-0293, Japan
Bunkyo-ku, Tokyo 113-8519, Japan
Bunkyo-ku, Tokyo 1138431, Japan
Meguro-ku, Tokyo 1538515, Japan
Shinjyuku-ku, Tokyo 162-8655, Japan
Toyoma, Toyama 930-0194, Japan
Guadajalara, Jalisco 44600, Mexico
Cordoba, Madrid 14004, Spain
Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan
Central Middlesbrough, Middlesbrough TS4 3BW, United Kingdom